Cassava Sciences Inc vs iShares Core MSCI EAFE ETF — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while iShares Core MSCI EAFE ETF trades at $96.36 (market cap $189.19B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 4801.8× Cassava Sciences Inc's market cap, and iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and iShares Core MSCI EAFE ETF for 40 Days on average.
| FLNA | IEFA | |
|---|---|---|
Market Cap | $39.40M | $189.19B |
Volume | 759,018 | 8,441,787 |
Sector | Health | Broad Market / Factor |
52-Week High | $4.64 | $101.41 |
52-Week Low | $0.68 | $85.06 |
Typical Hold Time | 37 Days | 40 Days |
Enterprise Value | -$43.28M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
IEFA, the iShares Core MSCI EAFE ETF, trades at $96.37, up 0.18% on the day, while technical indicators signal a bearish trend with moving averages and oscillators in sell territory. The fund provides exposure to developed markets outside North America, holding $196 billion in assets. Recent news highlights its role in international diversification strategies and comparisons with competing ETFs like Schwab's SCHF and State Street's SPDW.
The outlook for IEFA is influenced by global market sentiment and interest rate uncertainty, offering diversification benefits but facing headwinds from geopolitical tensions. Key risks include concentration in developed economies and currency fluctuations. Analyst comparisons favor IEFA for its scale and dividend yield, though expense ratios and performance relative to peers remain considerations for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →